Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNMNASDAQ:ELDNNASDAQ:IVANASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.43+2.1%$1.34$1.03▼$10.24$44.61M-0.24504,633 shs148,902 shsELDNEledon Pharmaceuticals$3.17+5.7%$3.28$2.00▼$5.54$189.83M0.08275,160 shs198,515 shsIVAInventiva$3.54-1.7%$3.21$1.53▼$4.05$185.77M0.862,883 shs18,855 shsPHATPhathom Pharmaceuticals$2.29-4.6%$4.77$2.21▼$19.71$159.49M0.151.09 million shs1.91 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals+1.45%-7.89%+14.75%+21.74%-81.82%ELDNEledon Pharmaceuticals+4.60%-5.00%+6.08%-36.80%+32.83%IVAInventiva+4.35%-2.70%+16.13%+44.00%+4.35%PHATPhathom Pharmaceuticals0.00%-44.06%-50.72%-59.32%-76.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNMActinium Pharmaceuticals1.2231 of 5 stars3.40.00.00.01.10.00.6ELDNEledon Pharmaceuticals2.1263 of 5 stars3.52.00.00.03.41.70.0IVAInventiva2.0625 of 5 stars3.41.00.00.03.21.70.6PHATPhathom Pharmaceuticals3.9606 of 5 stars4.53.00.00.02.25.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00179.72% UpsideELDNEledon Pharmaceuticals 3.00Buy$12.50294.32% UpsideIVAInventiva 2.80Moderate Buy$10.40193.79% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.60668.56% UpsideCurrent Analyst Ratings BreakdownLatest ATNM, ELDN, IVA, and PHAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $5.005/2/2025PHATPhathom PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.005/2/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $20.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/21/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/17/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $10.004/9/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/4/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $9.004/2/2025PHATPhathom PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/2/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/1/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium Pharmaceuticals$81K550.74N/AN/A$1.31 per share1.09ELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AIVAInventiva$9.20M20.20N/AN/A($0.67) per share-5.28PHATPhathom Pharmaceuticals$81.86M1.95N/AN/A($1.27) per share-1.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.39N/AN/AN/AN/A-100.85%-47.89%N/AELDNEledon Pharmaceuticals-$116.54M-$2.36N/AN/AN/AN/A-189.99%-28.17%5/8/2025 (Estimated)IVAInventiva-$119.51MN/A0.00N/AN/AN/AN/AN/AN/APHATPhathom Pharmaceuticals-$201.59M-$5.24N/AN/AN/A-1,292.14%N/A-79.57%N/ALatest ATNM, ELDN, IVA, and PHAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28N/AN/AN/AN/AN/A3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25ELDNEledon PharmaceuticalsN/A6.536.53IVAInventivaN/A0.590.59PHATPhathom PharmaceuticalsN/A5.735.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%ELDNEledon Pharmaceuticals56.77%IVAInventiva19.06%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%ELDNEledon Pharmaceuticals11.70%IVAInventiva32.00%PHATPhathom Pharmaceuticals24.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableIVAInventiva10052.48 million35.68 millionNot OptionablePHATPhathom Pharmaceuticals11069.65 million51.90 millionOptionableATNM, ELDN, IVA, and PHAT HeadlinesRecent News About These CompaniesAfter Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)May 8 at 10:35 AM | zacks.comAvidity Partners Management LP Lowers Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 6 at 7:39 AM | marketbeat.comThe Goldman Sachs Group Cuts Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $5.00May 5 at 3:34 AM | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Price Target Cut to $12.00 by Analysts at GuggenheimMay 5 at 3:34 AM | americanbankingnews.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price TargetMay 4, 2025 | finance.yahoo.comPhathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $20.00 at HC WainwrightMay 4, 2025 | marketbeat.comMarshall Wace LLP Takes $796,000 Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 4, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Buy" by BrokeragesMay 4, 2025 | americanbankingnews.comOracle Investment Management Inc. Reduces Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 3, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call TranscriptMay 3, 2025 | seekingalpha.comWhy Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 17.86%May 2, 2025 | aaii.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call TranscriptMay 2, 2025 | msn.comWhy Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 19.35%May 2, 2025 | aaii.comPhathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...May 2, 2025 | finance.yahoo.comRetail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 MissMay 2, 2025 | msn.comPhathom Pharmaceuticals Reports Q1 2025 Financial ResultsMay 2, 2025 | tipranks.comPhathom pharmaceuticals outlines VOQUEZNA expansion targets and cost-saving measures for profitability by 2026May 2, 2025 | msn.comPhathom cuts commercial chief, pares down DTC promotion in cost-saving driveMay 2, 2025 | fiercepharma.comPhathom Pharmaceuticals Eyes Profitability Amid GrowthMay 1, 2025 | tipranks.comPhathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comPhathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue EstimatesMay 1, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Quantum Computing: The $6.5 Billion Opportunity You Can’t IgnoreBy Jeffrey Neal Johnson | April 9, 2025View Quantum Computing: The $6.5 Billion Opportunity You Can’t IgnoreWalgreens Comeback? Private Equity Circling for a BuyoutBy Gabriel Osorio-Mazilli | April 13, 2025View Walgreens Comeback? Private Equity Circling for a BuyoutCan Disney’s Entertainment Division Overtake Its Theme Parks?By Jea Yu | April 21, 2025View Can Disney’s Entertainment Division Overtake Its Theme Parks?ATNM, ELDN, IVA, and PHAT Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.43 +0.03 (+2.14%) Closing price 04:00 PM EasternExtended Trading$1.45 +0.02 (+1.40%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Eledon Pharmaceuticals NASDAQ:ELDN$3.17 +0.17 (+5.67%) Closing price 04:00 PM EasternExtended Trading$3.17 0.00 (0.00%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Inventiva NASDAQ:IVA$3.54 -0.06 (-1.67%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Phathom Pharmaceuticals NASDAQ:PHAT$2.29 -0.11 (-4.58%) Closing price 04:00 PM EasternExtended Trading$2.34 +0.04 (+1.97%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
